Peptide Receptor Radionuclide Therapy (PRRT) uses a radiolabelled somatostatin analog that binds to receptors on tumour cells, combined with radioactive compounds, including 111Indium, 68Galiium, 90Yttrium, 177Lutetium, to deliver the killing effect of the radioactivity directly to the cell, avoiding destruction of healthy cells often found with external beam radiation.
The pCODR Expert Review Committee Final Recommendation was issued on August 01, 2019 – Reimburse with clinical criteria and/or conditions* for treatment of adult patients with somatostatin receptor positive ( SSR+) midgut neuroendocrine tumours (NETs ) whose disease has progressed on a somatostatin analogue and is unresectable ( see conditions )
pERC Final Recommendation
The INESSS recommendation was issued February 2019 – Funded as a Médicament d’exception for neuroendocrine tumours in the digestif tract or pancreatic well differentiated, advanced disease, non resectable or metastatic expressing the somatostatin receptor in adults. ( see conditions )
Advanced Accelerator Applications Canada, Inc. has launched an English and French website for patients and healthcare professionals to provide information on treatment with Lutathera.
Please visit: www.lutathera.ca
To get the Lutathera DIN, click on the attached Link: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
Enter Lutathera under product name.
NETTER-1 Study – Unmet need for long-term effective treatment of inoperable, gastro-entero-pancreatic neuroendocrine tumours (GEPNET).
This first Phase III trial compares 177Lu-DOTATATE with Octreotide (Sandostatin® LAR Depot) in patients with inoperable, progressive, somatostatin receptor positive midgut carcinoid tumours. 230 patients are divided into two groups of 115 each. The primary objective is to compare Progression Free Survival (PFS) between the groups. Secondary objectives are to compare Objective Response Rate, Overall Survival (OS), Time to Tumour Progression between groups, and to assess safety, tolerability and quality of life. 35 European and 15 U.S. sites are involved.
See trial details at: NETTER-1 STUDY
Advanced Accelerator Applications, AAA, has a new website regarding PRRT with Lutathera for both patients and providers: https://lutathera.com/. This website is intended for US residents only, there is a separate link for Non-US residents. There is also a separate section within the site for Healthcare Providers.